American College of Gastroenterology

Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.

In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

PROSE allows patients to report their symptoms of dysphagia in real-time.

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Patients with Crohn's disease often also suffer from kidney dysfunction.

This patient group had higher odds of death and longer lengths of hospital stays.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

The rates of adverse events was similar across all 4 indications in comparison to the placebo group.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

In a poster presented at ACG, investigators find a new patch test could help patients who are not responding to PPI therapy.

Longer studies are needed to determine the effectiveness and durability of CDI interventions.

In new data presented at ACG 2020, investigators report on the clinical characteristics and outcomes of chronic pancreatitis patients with CDI.

Rifaximin and lactulose did not result in clinically relevant changes to fecal microbial antibiotic susceptibility profiles.

Up to 91% of the gastroenterologist respondents plan to integrate telehealth into their practice following the COVID-19 pandemic.

In data presented at ACG 2020, researchers show a combination of sulindac and eflornithine could be effective for FAP patients.

Data suggests a more scrutinized follow-up period following surgery.

A new ACG study shows that 18% would have been considered low risk for NASH-F based on FAST score despite having high liver stiffness measurement.

Researchers examine he prevalence of and factors influencing EPI treatment with PERT in pancreatic cancer.

Girish Hiremath, MD, MPH, discusses a need to more accurately and objectively assess pediatric compliance to eosinophilic esophagitis therapies.

The CDC has standardized guidelines to help diagnose diarrhea, a potential indicator of c. difficile infection.

Female gender, Caucasian race, and older age were all significantly associated with microscopic colitis.